Skip to content

Diversity Analysis of Vaginal Microbiota on Women With High-risk Human Papillomavirus Infection

Diversity Analysis of Vaginal Microbiota on Women With High-risk Human Papillomavirus Infection and Cervical Cytological Abnormalities.

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03548740
Enrollment
151
Registered
2018-06-07
Start date
2018-09-01
Completion date
2020-05-20
Last updated
2019-02-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Papillomavirus Infections

Brief summary

Since other genital infections enhance HIV susceptibility by inducing inflammation, the investigators study the relationship between the vaginal microbiota composition and the risk of HPV infection, cervical cytological abnormalities.

Detailed description

Persistent infection with oncogenic Human Papillomavirus (HPV) is necessary but not sufficient for the development of cervical cancer. Additional factors correlated with HPV persistence include immunodeficiency caused by HIV, smoking, use of oral contraceptives and, more recently reported, vaginal dysbiosis. In a state of dysbiosis, there is a marked reduction of Lactobacillus and a high diversity of bacteria, with increased abundance of anaerobic bacterial species. Based on this, the investigators are going to analyze the changes of microbiota in women with high-risk HPV and the cervical lesions. And the investigators hope to figure out the difference and change in microbiota to realize the tanning of cervical lesions.

Interventions

BIOLOGICALHuman Papillomavirus

women with high-risk Human Papillomavirus or not

Sponsors

Peking Union Medical College Hospital
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
25 Years to 50 Years
Healthy volunteers
Yes

Inclusion criteria

Clinical diagnosis of HR-HPV results.

Exclusion criteria

Clinical diagnosis of vaginitis, immune disease, malignancy History of cervical lesions Pregnancy Clinical diagnosis of other serious systemic primary diseases, such as severe liver and kidney dysfunction Severe mental illness

Design outcomes

Primary

MeasureTime frameDescription
Vaginal microbiota and HR-HPV infection12 monthsThe persistence vaginal organism in HPV infection participants
Vaginal microbiota and the cervical lesion12 to 36 monthsThe cervical cytology, HPV and the vaginal microbiota were evaluated

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026